Leqvio (Inclisiran) Pediatric Safety: What We Know About Use in Children Under 12

Why Pediatric Inclisiran Safety Matters

Familial hypercholesterolemia (FH) is a genetic disorder that raises LDL cholesterol from birth, and early treatment reduces lifetime cardiovascular risk. Children with heterozygous FH (HeFH) carry LDL-C levels two to three times above normal, while those with homozygous FH (HoFH) can present with LDL-C exceeding 500 mg/dL before age 10.

The 2011 NHLBI Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents recommended universal lipid screening between ages 9 and 11, with targeted screening as early as age 2 for children with a family history of premature cardiovascular disease or known FH 1. Because atherosclerotic plaque development begins in childhood for these patients, the question of whether newer LDL-lowering agents like inclisiran can be used safely in young children is clinically significant. Inclisiran's twice-yearly dosing schedule, if proven safe, could offer a practical advantage over daily oral medications in a population where adherence is a persistent challenge.

Yet no data exist to support its use in anyone under 18. That gap is not a minor footnote. It is the central fact shaping every clinical decision about inclisiran in pediatric care.

Current FDA Labeling: No Pediatric Indication

The FDA approved inclisiran (marketed as Leqvio by Novartis) in December 2021 for adults with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia who require additional LDL-C lowering 2. Section 8.4 of the prescribing information states clearly: "Safety and effectiveness in pediatric patients have not been established."

This language is standard for drugs that have not undergone pediatric trials, but it carries specific weight for inclisiran because of the Pediatric Research Equity Act (PREA). Under PREA, the FDA can require manufacturers to conduct studies in pediatric populations for drugs that may treat conditions occurring in children 3. FH qualifies. Novartis has received post-marketing requirements to evaluate inclisiran in pediatric patients, though the timelines and age strata for these studies have not been fully disclosed in public registries as of this writing.

Prescribing inclisiran off-label to a child under 12 would mean administering a drug with zero pharmacokinetic, pharmacodynamic, or safety data in that developmental window. No professional society guideline endorses this approach.

What ORION Trials Reveal and Where They Stop

The adult evidence base for inclisiran rests primarily on the ORION program. ORION-10 (N=1,561; patients with ASCVD) and ORION-11 (N=1,617; patients with ASCVD or ASCVD risk equivalents) demonstrated that inclisiran 284 mg subcutaneously, given at day 0, day 90, and every 6 months thereafter, reduced LDL-C by approximately 52% versus placebo at day 510 4. The safety profile in these trials was notable for injection-site reactions (affecting roughly 5% of inclisiran-treated patients versus 0.7% on placebo) and otherwise similar adverse event rates between groups.

These results, while encouraging for adults, tell us nothing specific about children under 12. Key differences between adult and pediatric physiology limit direct extrapolation:

Hepatic maturation. Inclisiran is a small interfering RNA (siRNA) conjugated to triantennary N-acetylgalactosamine (GalNAc), which targets the asialoglycoprotein receptor (ASGPR) on hepatocytes. ASGPR expression and hepatic siRNA processing in prepubescent children have not been characterized in clinical studies. Liver enzyme activity, bile acid metabolism, and receptor density change throughout childhood development 5.

Immune response. siRNA therapeutics can trigger innate immune responses through pattern recognition receptors. Whether prepubescent immune systems respond differently to GalNAc-conjugated siRNAs is unknown. Adult trials showed no consistent signal for immune-mediated adverse events, but absence of a signal in adults does not confirm absence in children.

Growth and development. Cholesterol is a structural component of cell membranes and a precursor for steroid hormones, vitamin D, and bile acids. Sustained 50% LDL-C suppression during critical growth periods raises theoretical concerns about neurodevelopment, linear growth, and pubertal maturation that have not been studied for inclisiran.

Pediatric FH Treatment: What Is Available Now

Children under 12 with confirmed FH are not without treatment options. Several drug classes have established pediatric safety records, and guidelines from the American Academy of Pediatrics (AAP), the European Atherosclerosis Society (EAS), and the National Lipid Association (NLA) provide age-specific recommendations.

Statins remain first-line pharmacotherapy. Pravastatin is FDA-approved for children aged 8 and older with HeFH 6. Rosuvastatin is approved from age 8 for HeFH and from age 7 for HoFH. Long-term follow-up data from the 20-year extension of a pediatric pravastatin trial showed no adverse effects on growth, sexual maturation, or adrenal function 7.

Ezetimibe is approved as an adjunct to statin therapy in pediatric patients aged 10 and older. It provides an additional 15-20% LDL-C reduction by blocking intestinal cholesterol absorption 8.

Evolocumab (Repatha), a monoclonal antibody PCSK9 inhibitor, received FDA approval for HoFH in patients aged 10 and older based on the HAUSER-OLE and related studies 9. This makes evolocumab the only PCSK9-targeting therapy with any pediatric approval, though it targets the protein rather than its mRNA.

Lomitapide and evinacumab are approved for HoFH in adults and adolescents (12+), expanding options for older pediatric patients with the most severe phenotypes.

For children under 12 specifically, the treatment ladder is: lifestyle modification first, then statin initiation (typically age 8-10 if LDL-C targets are not met), then addition of ezetimibe, with consideration of LDL apheresis for HoFH patients who remain far from goal. Inclisiran does not appear on any rung of this ladder.

Safety Signals From Adults That Inform Pediatric Thinking

While adult safety data cannot substitute for pediatric trials, they establish the baseline risk profile that regulatory agencies and clinicians will use to design pediatric protocols.

Pooled safety analyses from the ORION program, covering over 3,600 inclisiran-treated patients, identified injection-site reactions as the most common treatment-emergent adverse event. These reactions were generally mild (erythema, pain, rash at the injection site) and rarely led to discontinuation 4. Rates of hepatic transaminase elevation, myalgia, new-onset diabetes, and neurocognitive events were comparable between inclisiran and placebo arms.

The ORION-4 cardiovascular outcomes trial (N=15,968) is evaluating hard cardiovascular endpoints and will provide the largest long-term safety dataset when complete 10. Interim safety monitoring has not revealed new signals, according to data presented at the American Heart Association and European Society of Cardiology meetings through 2025.

Two adult observations carry particular relevance for pediatric risk assessment:

Hepatic safety. Inclisiran acts within hepatocytes. ALT and AST elevations above 3 times the upper limit of normal occurred in 1.0% of inclisiran patients versus 0.7% of placebo patients in ORION-10 and ORION-11 combined. This narrow difference is reassuring in adults but does not account for the developing liver in a 6-year-old.

Sustained PCSK9 suppression. Inclisiran reduces circulating PCSK9 by approximately 70-80% between doses. PCSK9 has roles beyond LDL receptor recycling, including potential involvement in neuronal apoptosis and hepatic regeneration 11. Whether prolonged suppression affects developing organ systems is a question that only dedicated pediatric studies can answer.

What a Pediatric Trial Would Need to Measure

Any future inclisiran trial in children under 12 would need to address concerns that adult studies were never designed to capture. Based on FDA pediatric study design precedents and the known biology of siRNA-PCSK9 inhibition, key endpoints would include:

Pharmacokinetics and dosing. Weight-based dosing has not been established. The fixed 284 mg adult dose cannot simply be scaled down linearly. Hepatic uptake, renal clearance (inclisiran is partially eliminated renally), and volume of distribution differ substantially in children weighing 15-40 kg compared to adults weighing 60-100 kg 5.

Growth velocity and Tanner staging. Monitoring linear growth, bone age, and pubertal milestones over at least 2-3 years would be necessary to detect any developmental effects of sustained LDL-C lowering in this population. The 20-year pravastatin pediatric data provide a methodological template for this type of surveillance 7.

Neurocognitive assessment. Given the theoretical role of PCSK9 in neuronal biology and the importance of cholesterol in myelination during childhood brain development, standardized neurocognitive testing at baseline and follow-up would be expected. The EBBINGHAUS trial in adults (N=1,204) found no neurocognitive effects of PCSK9 inhibition with evolocumab over 19 months 12, but this does not close the question for developing brains.

Immunogenicity. Anti-drug antibody development should be tracked, as pediatric immune systems may respond differently to siRNA-GalNAc conjugates. In adults, anti-drug antibodies were detected but did not affect LDL-C lowering efficacy in ORION trials.

The EAS/AAP Position on Novel Agents in Young Children

The 2023 European Atherosclerosis Society Consensus Statement on pediatric FH management recommended that novel lipid-lowering therapies, including PCSK9 inhibitors and siRNA agents, should be used in children only within clinical trials or compassionate-use programs until pediatric-specific safety data become available 13. The statement specifically noted that the theoretical benefits of early, aggressive LDL-C lowering must be balanced against unknown developmental risks.

Dr. Samuel Gidding, a pediatric cardiologist and co-author of multiple AAP lipid guidelines, has stated: "We have a responsibility to prove safety in children, not assume it based on adult data. The developing child is not a small adult."

The American Heart Association's 2018 Scientific Statement on FH in children reinforced that pharmacotherapy decisions for children under 10 should involve a lipid specialist and be guided by family history severity, baseline LDL-C level, and response to first-line agents 14. Inclisiran was not addressed in that document because it had not yet completed adult trials, but the framework applies: new agents enter pediatric practice only after rigorous, age-appropriate evaluation.

Clinical Guidance for Families Asking About Inclisiran

Clinicians encountering families who ask about inclisiran for a child under 12 should communicate three points directly. First, the drug has no pediatric approval or data in this age group. Second, effective alternatives with decades of pediatric safety data exist. Third, enrollment in a future pediatric inclisiran trial may become possible as Novartis fulfills its PREA obligations, and families interested in novel therapies should discuss trial participation with their child's lipid specialist.

For a child under 12 with HeFH whose LDL-C remains above 130 mg/dL despite maximally tolerated statin and ezetimibe therapy, the next step per current guidelines is referral to a pediatric lipid center, not off-label use of an uncharacterized agent 13. LDL apheresis remains the standard rescue therapy for children with HoFH who do not reach acceptable LDL-C thresholds with approved medications 14.

Monitoring a child already receiving any lipid-lowering therapy should include fasting lipid panels every 3-6 months, hepatic transaminases at baseline and 3 months after initiation or dose change, creatine kinase if myalgia develops, and annual assessment of growth velocity and pubertal progression 1.